# A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma

> **NCT00190762** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 240 (—)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT00190762
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 240 (—)
- **Last updated:** 2007-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00190762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00190762, "A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT00190762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*